Skip to main content
$0.62 -0.06 (-9.09%) At close · Jul 22
Market Cap
$182.69M
Shares
294.61M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.62 Open$0.68 Day$0.60–0.69 52W$0.48–3.07 Avg vol 30d5.7M Short int27.4M · 9.3% float · 3.6d Short vol30% Last earningsMay 14, 2026 DataAug 2021–Jul 2026 Filing10-Q · May 14

Up next

Next earnings call
Sep 1, 2026 Est · unconfirmed · in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 18.7 · elevated Equity put/call 0.61
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −63%
      below
      Price vs 50-day avg −37%
      below
      RSI (14) 29
      oversold
      MACD trend Negative
      52-week position 5%
      near low
      Volume (OBV) Bullish div.
      accumulating
      Momentum
      relative strength
      Very Weak
      1-month return −34%
      trailing
      6-month return −68%
      trailing
      YTD return −75%
      this year
      Relative strength −75%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      8 of 140 funds reported for Jun 30 · net +45.5K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      9.31% of float · ▼ -20.3% MoM · 3.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      140 holders — near 3-yr high, broad support
      Squeeze score 56
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +110%
      Y/Y
      EPS growth +79%
      Y/Y
      Free cash flow $-58.3M
      Balance sheet $226.7M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 142%
      annualized · 1-yr
      Max drawdown −78%
      past year
      ATR 12.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      4 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −63% Bearish
      Price vs 50-day avg
      −37% Bearish
      RSI (14)
      29 Neutral
      MACD trend
      Negative Bearish
      52-week position
      5% Bearish
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      8 of 140 funds reported for Jun 30 · net +45.5K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      9.31% of float · ▼ -20.3% MoM · 3.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      140 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $0 Now $1 · 5% 52-wk high $3
      vs 200-day avg -63% vs 50-day avg -37%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IVVD
      Invivyd, Inc.
      this stock
      $182.69M -74.9% +110.5% 9.3%
      ONC
      BeOne Medicines Ltd.
      $462.38B +5.3% +22179.2% 941.0 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $119.94B +4.2% +46.2% 28.1 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $68.27B -15.5% +20.8% 15.9 3.3%
      ARGX
      Argenx SE
      $57.84B +9.9% 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      139
      % held
      77.1%
      Reported
      8 of 140
      Top holder
      JANUS HENDERSON GROUP PLC
      Held Float
      View
      Held by Funds
      Fund positions
      31
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      27.4M
      Days to cover
      3.6d
      Change
      -7.0M sh
      View
      Short Volume
      Short vol %
      30%
      As of
      Jul 23, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      6.5K
      Value
      $5.0K
      As of
      Jun 15, 2026
      View
      Off-Exchange
      Off-exchange %
      57.5%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $53.4M
      Net income (FY)
      $-52.5M
      EPS diluted
      $-0.30
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 6, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $103.0K
      Shares
      66.0K
      Filed
      Feb 17, 2026
      View
      Exempt Offerings
      Offering
      $23.7M
      Filed
      Nov 29, 2022
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      IVVD -24.1% -33.7% -67.7% -28.9% -74.9%
      SPY -1.0% +1.9% +7.5% +0.1% +9.6%
      vs SPY -23.1% -35.6% -75.2% -29.0% -84.5%
      Key facts CIK 1832038 CUSIP 00534A102 13F (30d) 7 filings 7 filers Visit website Investor relations